Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants
In late-stage tuberculosis vaccine trials among adults and adolescents, pre-enrolment screening by IGRA testing provides a large sample size efficiency when M. tuberculosis transmission levels are relatively low, but modest or no sample size benefits at high transmission levels.
Authors
- Mark Hatherill (ORCID: https://orcid.org/0000-0003-3491-1809)
- Frank G. J. Cobelens (ORCID: https://orcid.org/0000-0002-4367-1133)
- Gavin Churchyard (ORCID: https://orcid.org/0000-0002-4269-3699)
- Puck T. Pelzer (ORCID: https://orcid.org/0000-0003-1648-0304)
- Philip C. Hill (ORCID: https://orcid.org/0000-0002-7006-0549)
- Alberto L. García‐Basteiro (ORCID: https://orcid.org/0000-0002-2038-5505)
- Richard Guy White (ORCID: https://orcid.org/0000-0003-4410-6635)
- Leonardo Martínez (ORCID: https://orcid.org/0000-0003-0954-8489)
Institutions
- Boston University (US)
- University of Cape Town (ZA)
- London School of Hygiene & Tropical Medicine (GB)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- South African Tuberculosis Vaccine Initiative (ZA)
- Aurum Institute (ZA)
- Amsterdam Institute for Global Health and Development (NL)
- Atria (NL)
- University of Otago (NZ)
Publication Details
- Journal
- Vaccine
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127301
- Citations
- 2
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 2.79